Diabetic ketoacidosis and related events in the canaglif lozin type 2 diabetes clinical program. Diabetes care 2015;38:1680-1686
Journal
Diabetes Care
Journal Volume
38
Journal Issue
11
Pages
e198
Date Issued
2015
Author(s)
SDGs
Other Subjects
C peptide; canagliflozin; glucose; antidiabetic agent; canagliflozin; acidosis; autoimmune disease; B lymphocyte; clinical feature; diabetic ketoacidosis; disease association; glucose blood level; health program; human; hyperglycemia; non insulin dependent diabetes mellitus; Note; patient care; risk factor; United States; chemically induced; Diabetes Mellitus, Type 2; diabetic ketoacidosis; female; male; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Humans; Hypoglycemic Agents; Male
Publisher
American Diabetes Association Inc.
Type
note